Literature DB >> 25942

Transplantation of allogeneic bone marrow without graft-versus-host disease using total lymphoid irradiation.

S Slavin, Z Fuks, H S Kaplan, S Strober.   

Abstract

Bone marrow (BM) and skin allografts from C57BL/Ka (H-2b/b) mice were transplanted to BALB/c (H-2d/d) recipients treated with total lymphoid irradiation (TLI), whole-body irradiation (WBI), or fractionated thymic irradiation TLI prolonged skin allograft survival about five times as long as that in untreated controls, and allowed for permanent engraftment of BM cells in approximately equal to 90% of recipients. None of the BM recipients showed clinical signs of graft-versus-host disease (GVHD) (diarrhea, weight loss, hunched back, etc.). On the other hand, recipients given WBI and allogeneic BM cells developed severe clinical GVHD. The majority of the latter recipients died within 12 days after BM transplantation, and 95% died within 61 days. Although TLI protected BALB/c mice against GVHD induced by BM cells, all recipients given TLI and allogeneic spleen cells developed lethal GVHD. Thymic irradiation alone marginally prolonged skin allograft survival, and did not allow for allogeneic BM engraftment. These results suggest that TLI may be a useful regimen in clinical BM transplantation, since this form of radiotherapy is used extensively in humans and has few severe side effects.

Entities:  

Mesh:

Year:  1978        PMID: 25942      PMCID: PMC2184246          DOI: 10.1084/jem.147.4.963

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  10 in total

Review 1.  Allograft reaction against H-2-region antigens.

Authors:  J Klein
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

2.  Bone marrow transplantation in rats across strong histocompatibility barriers by selective elimination of lymphoid cells in donor marrow.

Authors:  W Müller-Ruchholtz; H U Wottge; H K Müller-Hermelink
Journal:  Transplant Proc       Date:  1976-12       Impact factor: 1.066

3.  Use of total lymphoid irradiation in tissue transplantation in mice.

Authors:  S Slavin; S Strober; Z Fuks; H S Kaplan
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

4.  Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease.

Authors:  R J Lukes; B H Tindle
Journal:  N Engl J Med       Date:  1975-01-02       Impact factor: 91.245

5.  Hemopoietic reconstitution obtained in F1 hybrids by grafting of parental marrow cells.

Authors:  H von Boehmer; J Sprent; M Nabholz
Journal:  Transplant Proc       Date:  1976-09       Impact factor: 1.066

6.  Marrow grafts between histoincompatible canine family members.

Authors:  R Storb; H J Kolb; T C Graham; R Leblond; H Kolb; K G Lerner; E D Thomas
Journal:  Rev Eur Etud Clin Biol       Date:  1972 Aug-Sep

7.  Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. I. Stimulation by phytohaemagglutinin.

Authors:  D Roos; J A Loos
Journal:  Biochim Biophys Acta       Date:  1970-12-29

8.  Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation.

Authors:  S Slavin; S Strober; Z Fuks; H S Kaplan
Journal:  Science       Date:  1976-09-24       Impact factor: 47.728

9.  Anti-lymphocytic antibodies and marrow transplantation. 3. Effect of heterologous anti-brain antibodies on acute secondary disease in mice.

Authors:  H Rodt; S Thierfelder; M Eulitz
Journal:  Eur J Immunol       Date:  1974-01       Impact factor: 5.532

10.  Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts.

Authors:  S Slavin; S Strober; Z Fuks; H S Kaplan
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

  10 in total
  26 in total

Review 1.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 2.  Path to clinical transplantation tolerance and prevention of graft-versus-host disease.

Authors:  Samuel Strober
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 3.  The early history of Stanford Immunology.

Authors:  Patricia P Jones; Leonore A Herzenberg
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

4.  Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation.

Authors:  J Mattsson; M Uzunel; M Remberger; L Tammik; B Omazic; V Levitsky; J Z Zou; P Hentschke; O Ringdén
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

5.  Total lymphoid irradiation in renal transplantation.

Authors:  J A Myburgh; J A Smit; A M Meyers; J R Botha; S Browde; P D Thomson
Journal:  World J Surg       Date:  1986-06       Impact factor: 3.352

Review 6.  The use of total lymphoid irradiation for allogeneic bone marrow transplantation in animals and man.

Authors:  S Slavin; R Or; Z Weshler; Z Fuks; S Morecki; M Weigensberg; S Bar; L Weiss
Journal:  Surv Immunol Res       Date:  1985

7.  Proceedings of the Annual Meeting of the European Foundation for Bone Marrow Transplantation, Sils Maria (Engadine), Switzerland, April 13-16, 1980.

Authors: 
Journal:  Blut       Date:  1980-09

Review 8.  Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation.

Authors:  Shimon Slavin
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

9.  Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation.

Authors:  S Slavin
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

10.  Regulation of the immune response in experimental models of autoimmune disorders: resistance of (NZB X NZW)F1 mice to tolerance induction in vivo.

Authors:  I Zan-Bar; M Barzilay; M Moscovitch; S Slavin
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.